

The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA SHINEWAY PHARMACEUTICAL GROUP LIMITED

中國神威藥業集團有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 2877)

RESULTS OF EXTRAORDINARY GENERAL MEETING DISCLOSEABLE AND CONNECTED TRANSACTION

The Directors announced that the ordinary resolution proposed at the EGM held on 12 May 2005 in relation to the Acquisition (as set out in the ordinary resolution in the EGM Notice dated 19 April 2005) was approved by the Independent Shareholders at the EGM by poll. At the EGM, Sinovest and its Associates abstained from voting in respect of the ordinary resolution proposed at the EGM as required under the Listing Rules.

Reference is made to the announcement of the Company dated 30 March 2005, the circular (the "Circular") and the EGM Notice of the Company both dated 19 April 2005. Capitalised terms used in this announcement shall have the same meaning as defined in the Circular unless otherwise defined herein.

The Directors announced that the ordinary resolution proposed at the EGM held on 12 May 2005 in relation to the Acquisition (as set out in the ordinary resolution in the EGM Notice dated 19 April 2005) was approved by the Independent Shareholders at the EGM by poll.

As at the date of the EGM, the total issued share capital of the Company was 830,000,000 Shares, of which 600,000,000 Shares were owned by Sinovest. The total number of Shares entitling the Independent Shareholders to attend and vote for or against the ordinary resolution were 230,000,000 Shares, out of which Independent Shareholders holding 103,641,962 Shares attended and voted at the EGM. Sinovest and its Associates (who beneficially own a total of 600,000,000 Shares) abstained from voting in respect of the ordinary resolution proposed at the EGM as required under the Listing Rules. The

vote-taking at the EGM was scrutinized by Computershare Hong Kong Investor Services Limited, the share registrar of the Company. The particulars of the voting result for the ordinary resolution are set out as follows:

Ordinary Resolution	No. of Votes (%)	
	For	Against
To approve the Equity Interest Transfer Agreement (股權轉讓協議) dated 30 March 2005 entered into between Yuan Da International Limited (遠大國際有限公司) (“Yuan Da”), being a wholly-owned subsidiary of the Company, as purchaser, and 神威醫藥科技(廊坊)有限公司 (Shineway Medical Science & Technology (Lang Fang) Co., Ltd.) (“Shineway Lang Fang”) as vendor in respect of the acquisition of 20% of the equity interest in 神威藥業營銷有限公司 (Shineway Pharmaceutical Sales Co., Ltd.) by Yuan Da from Shineway Lang Fang and the consideration for such acquisition under the Equity Interest Transfer Agreement and all transactions contemplated thereunder as well as the terms and conditions thereof.	103,641,962 Shares (100%)	Nil Shares (0%)

As 100% of the votes were cast in favour of the ordinary resolution proposed at the EGM, the resolution was duly passed.

By Order of the Board
Li Zhenjiang
Chairman

Hong Kong, 12 May 2005

As at the date of this announcement, the executive Directors are Mr. Li Zhenjiang, Ms. Wang Zhihua, Ms. Xin Yunxia, Mr. Hou Jiangtao and Mr. Li Huimin and the independent non-executive Directors are Mr. Li Kung Man, Dr. Wang Jianping and Prof. Zhou Chaofan.